Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML

R. M. Saliba, Krishna V Komanduri, S. Giralt, J. de Souza, P. Patah, B. Oran, D. Couriel, G. Rondon, R. E. Champlin, M. de Lima

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Lymphocyte and platelet recovery may influence outcomes of allo-SCT for treatment of AML. It is not clear, however, if this impact is independent of patient and transplant characteristics. To investigate this question, we evaluated the influence of pre- or post transplant factors on day +30 absolute lymphocyte count (ALC) and the speed of platelet engraftment. We studied 106 AML patients treated with fludarabine and melphalan reduced-intensity conditioning and allo-SCT. Twenty nine percent of patients were in CR at the initiation of the conditioning, 39% had active disease with circulating blasts and 32% had active disease without circulating blasts. The graft source was peripheral blood from a matched sibling donor in 55% and BM from a matched unrelated donor in 45%. Our data showed that the presence of circulating blasts before transplantation is significantly correlated with low post-SCT day +30 ALC and slow platelet engraftment. This finding suggests that the impact of early ALC and platelet recovery on transplant outcome may not be independent of disease status at transplantation.

Original languageEnglish
Pages (from-to)685-692
Number of pages8
JournalBone Marrow Transplantation
Volume43
Issue number9
DOIs
StatePublished - Jan 1 2009
Externally publishedYes

Fingerprint

Lymphocyte Count
Leukemia
Blood Platelets
Lymphocytes
Transplants
Transplantation
Unrelated Donors
Melphalan
Siblings
Tissue Donors
Conditioning (Psychology)
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Saliba, R. M., Komanduri, K. V., Giralt, S., de Souza, J., Patah, P., Oran, B., ... de Lima, M. (2009). Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML. Bone Marrow Transplantation, 43(9), 685-692. https://doi.org/10.1038/bmt.2008.376

Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML. / Saliba, R. M.; Komanduri, Krishna V; Giralt, S.; de Souza, J.; Patah, P.; Oran, B.; Couriel, D.; Rondon, G.; Champlin, R. E.; de Lima, M.

In: Bone Marrow Transplantation, Vol. 43, No. 9, 01.01.2009, p. 685-692.

Research output: Contribution to journalArticle

Saliba, RM, Komanduri, KV, Giralt, S, de Souza, J, Patah, P, Oran, B, Couriel, D, Rondon, G, Champlin, RE & de Lima, M 2009, 'Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML', Bone Marrow Transplantation, vol. 43, no. 9, pp. 685-692. https://doi.org/10.1038/bmt.2008.376
Saliba, R. M. ; Komanduri, Krishna V ; Giralt, S. ; de Souza, J. ; Patah, P. ; Oran, B. ; Couriel, D. ; Rondon, G. ; Champlin, R. E. ; de Lima, M. / Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML. In: Bone Marrow Transplantation. 2009 ; Vol. 43, No. 9. pp. 685-692.
@article{b72bdefcd77a4d19b7e58cb2fb969290,
title = "Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML",
abstract = "Lymphocyte and platelet recovery may influence outcomes of allo-SCT for treatment of AML. It is not clear, however, if this impact is independent of patient and transplant characteristics. To investigate this question, we evaluated the influence of pre- or post transplant factors on day +30 absolute lymphocyte count (ALC) and the speed of platelet engraftment. We studied 106 AML patients treated with fludarabine and melphalan reduced-intensity conditioning and allo-SCT. Twenty nine percent of patients were in CR at the initiation of the conditioning, 39{\%} had active disease with circulating blasts and 32{\%} had active disease without circulating blasts. The graft source was peripheral blood from a matched sibling donor in 55{\%} and BM from a matched unrelated donor in 45{\%}. Our data showed that the presence of circulating blasts before transplantation is significantly correlated with low post-SCT day +30 ALC and slow platelet engraftment. This finding suggests that the impact of early ALC and platelet recovery on transplant outcome may not be independent of disease status at transplantation.",
author = "Saliba, {R. M.} and Komanduri, {Krishna V} and S. Giralt and {de Souza}, J. and P. Patah and B. Oran and D. Couriel and G. Rondon and Champlin, {R. E.} and {de Lima}, M.",
year = "2009",
month = "1",
day = "1",
doi = "10.1038/bmt.2008.376",
language = "English",
volume = "43",
pages = "685--692",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML

AU - Saliba, R. M.

AU - Komanduri, Krishna V

AU - Giralt, S.

AU - de Souza, J.

AU - Patah, P.

AU - Oran, B.

AU - Couriel, D.

AU - Rondon, G.

AU - Champlin, R. E.

AU - de Lima, M.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Lymphocyte and platelet recovery may influence outcomes of allo-SCT for treatment of AML. It is not clear, however, if this impact is independent of patient and transplant characteristics. To investigate this question, we evaluated the influence of pre- or post transplant factors on day +30 absolute lymphocyte count (ALC) and the speed of platelet engraftment. We studied 106 AML patients treated with fludarabine and melphalan reduced-intensity conditioning and allo-SCT. Twenty nine percent of patients were in CR at the initiation of the conditioning, 39% had active disease with circulating blasts and 32% had active disease without circulating blasts. The graft source was peripheral blood from a matched sibling donor in 55% and BM from a matched unrelated donor in 45%. Our data showed that the presence of circulating blasts before transplantation is significantly correlated with low post-SCT day +30 ALC and slow platelet engraftment. This finding suggests that the impact of early ALC and platelet recovery on transplant outcome may not be independent of disease status at transplantation.

AB - Lymphocyte and platelet recovery may influence outcomes of allo-SCT for treatment of AML. It is not clear, however, if this impact is independent of patient and transplant characteristics. To investigate this question, we evaluated the influence of pre- or post transplant factors on day +30 absolute lymphocyte count (ALC) and the speed of platelet engraftment. We studied 106 AML patients treated with fludarabine and melphalan reduced-intensity conditioning and allo-SCT. Twenty nine percent of patients were in CR at the initiation of the conditioning, 39% had active disease with circulating blasts and 32% had active disease without circulating blasts. The graft source was peripheral blood from a matched sibling donor in 55% and BM from a matched unrelated donor in 45%. Our data showed that the presence of circulating blasts before transplantation is significantly correlated with low post-SCT day +30 ALC and slow platelet engraftment. This finding suggests that the impact of early ALC and platelet recovery on transplant outcome may not be independent of disease status at transplantation.

UR - http://www.scopus.com/inward/record.url?scp=67349089989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349089989&partnerID=8YFLogxK

U2 - 10.1038/bmt.2008.376

DO - 10.1038/bmt.2008.376

M3 - Article

C2 - 19011667

AN - SCOPUS:67349089989

VL - 43

SP - 685

EP - 692

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 9

ER -